
Novo Nordisk has closed the acquisition deal of Dicerna Pharmaceuticals, with which the Danish firm has collaborated to develop potential RNA drugs since 2019, Novo Nordisk announces in a press release on Tuesday.
Shares of Dicerna, which is based in Boston, have been purchased at a price of USD 38.25 dollars apiece, equating to USD 3.3bn, making this Novo Nordisk's single-biggest buy ever.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app